Hydroxocobalamin for Neuroprotection in a Hemorrhagic Swine Model Traumatic Brain Ischemia: POI and ERC Care
Abstract
Traumatic hemorrhage is a leading cause of death in the military and civilian environment. Occurrence of Traumatic Brain Injury (TBI), concurrently with hypotension is associated with poor prognosis. TBI and global brain ischemia (GBI) cause many of the same injures in the brain. We have shown that pre-clinical treatment with Hydroxocobalamin (HOC), is as effective as whole blood and Hextend in maintaining mean arterial pressure (MAP) in a swine model of hemorrhage. Our intention was to determine any neuroprotective effects that HOC may have provided in models of TBI or GBI with hypotension. Based on previous studies with HOC, we anticipated that it was valuable to pursue research endeavors with HOC. We hypothesized that 1) hemorrhaged swine treated with HOC after cardiac arrest or TBI will show normal behavior during the 72 hour observation period (as determined by a neurologic severity score); 2) that brain injury biomarkers will decrease over time in hemorrhaged swine treated with HOC and; 3) GBI or TBI animals treated with HOC will show less brain damage compared to untreated animals, as determined by a certified veterinary pathologist. In preparation for the execution of this project, several problems were encountered that caused delays, ultimately leading to study closure. This included 1) a two-year delay with no resolution, on the acquisition of the TBI cortical impact device (PCI3000, Hatteras Instruments). As a result, a new TBI model/device was proposed, supplies were ordered and bench tests on swine carcasses began in December 2019. 2) For model refinement of the new TBI device, those bench tests required leveraging swine carcasses left from other protocols at the CIRS laboratory.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 10, 2020
- Accession Number
- AD1165089
Entities
People
- Joseph K Maddry
Organizations
- 59th Medical Wing